轻度认知障碍伴路易体、阿尔茨海默病及年龄匹配对照者的系列黑质纹状体多巴胺能成像
研究纳入20例阿尔茨海默病所致轻度认知障碍(MCI-AD)、11例可能MCI-LB、25例很可能MCI-LB和29例年龄匹配对照,基线与年度随访行123[I]-FP-CIT SPECT。很可能MCI-LB组纹状体SBR年变化为-0.48(95%CI -0.89至-0.06),对照组为0.23(95%CI -0.07至0.53);对照组重测变异平均12%(SD 5.5%),作者认为个体层面变化诊断价值有限。
要点
- 很可能MCI-LB组纹状体SBR年变化为-0.48(95%CI -0.89至-0.06),对照组为0.23(95%CI -0.07至0.53)。
- MCI-LB组SBR年百分比变化中位数为-5.6%(95%CI -8.2%至-2.9%),MCI-AD组为2.1%(95%CI -3.5%至8.0%)。
- 对照组重测变异平均12%(SD 5.5%),作者认为个体层面纹状体摄取变化诊断价值有限。
核心结论
- 在组水平上,123[I]-FP-CIT SPECT可检测到MCI-LB患者纹状体进行性多巴胺能丢失。
- 作者认为,由于重测变异高,临床实践中个体纹状体123[I]-FP-CIT摄取变化似乎诊断价值有限。
研究设计与样本
- 研究纳入20例MCI-AD、11例可能MCI-LB、25例很可能MCI-LB和29例年龄匹配对照。
- 受试者接受全面临床评估、基线与年度随访123[I]-FP-CIT SPECT,以及基线心脏123碘-间碘苄胍(I-MIBG)检查。
- 采用混合效应模型比较各诊断组与对照组纹状体123[I]-FP-CIT特异性结合比(SBR)的变化。
- 可能和很可能MCI-LB组达到纹状体摄取低于年龄匹配对照2个标准差的时间被定义为出现定量异常123[I]-FP-CIT SPECT的间隔时间。
- 利用对照组基线与重复扫描评估重测变异。
主要发现
- 基线与末次图像平均间隔1.6年(SD=0.9,范围1.0-4.3)。
- SBR年估计变化:对照组0.23(95%CI -0.07至0.53),MCI-AD组-0.09(95%CI -0.55至0.36),可能MCI-LB组-0.50(95%CI -1.03至0.04),很可能MCI-LB组-0.48(95%CI -0.89至-0.06)。
- MCI-LB组SBR年百分比变化中位数为-5.6%(95%CI -8.2%至-2.9%),MCI-AD组为2.1%(95%CI -3.5%至8.0%)。
- 正常扫描变为异常的推断时间为6年。
- 对照组和MCI-AD组多巴胺能结合随时间无显著变化。
关键数值与推荐
- 研究提供II级证据:123[I]-FP-CIT SPECT测量的纹状体摄取纵向下降与路易体病所致MCI相关,而与阿尔茨海默病所致MCI无关。
临床怎么用
- 作者认为,由于重测变异高,临床实践中个体纹状体123[I]-FP-CIT摄取变化似乎诊断价值有限。
局限性
- 对照组重测变异平均12%(SD 5.5%),作者据此提醒不要过度解读重复扫描中的小变化。
- 作者指出,由于重测变异高,个体纹状体123[I]-FP-CIT摄取变化在临床实践中似乎诊断价值有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Progressive nigrostriatal pathway degeneration occurs in individuals with dementia with Lewy bodies (LB). Our objective was to investigate whether repeat 123[I]-N-(3-fluoropropyl)-2β-carboxymethoxy-3β-(4-iodophenyl) nortropane (FP-CIT) single photon emission computed tomography (SPECT) can identify progressive dopaminergic loss in mild cognitive impairment (MCI) with Lewy bodies (MCI-LB). METHODS: Individuals with MCI-LB and MCI due to Alzheimer disease (MCI-AD) underwent comprehensive clinical assessment, 123[I]-FP-CIT SPECT at baseline and annual reviews, and baseline cardiac 123 iodine metaiodobenzylguanidine (I-MIBG). Mixed-effects models were used to investigate changes in 123[I]-FP-CIT specific binding ratio (SBR) in the striatum for each diagnostic group compared with controls. The time interval to the development of a quantitatively abnormal 123[I]-FP-CIT SPECT in the possible and probable MCI-LB groups was determined as the time it took for these groups to reach a striatal uptake 2 SDs below aged-matched controls. Test-retest variation was assessed using baseline and repeat scans in controls. RESULTS: We recruited 20 individuals with MCI-AD, 11 with possible MCI-LB, 25 with probable MCI-LB, and 29 age-matched controls. The mean time between baseline and the final image was 1.6 years (SD = 0.9, range 1.0-4.3). The annual estimated change in SBR was 0.23 for controls (95% CI -0.07 to 0.53), -0.09 (-0.55 to 0.36) for MCI-AD, -0.50 (-1.03 to 0.04) for possible MCI-LB, and -0.48 (-0.89 to -0.06) for probable MCI-LB. The median annual percentage change in SBR in MCI-LB was -5.6% (95% CI -8.2% to -2.9%) and 2.1% (-3.5% to 8.0%) for MCI-AD. The extrapolated time for a normal scan to become abnormal was 6 years. Controls and MCI-AD showed no significant change in dopaminergic binding over time. The mean test-retest variation in controls was 12% (SD 5.5%), which cautions against overinterpretation of small changes on repeat scanning. DISCUSSION: Progressive dopaminergic loss in the striatum is detectable using 123[I]-FP-CIT SPECT in MCI-LB at a group level. In clinical practice, individual change in striatal 123[I]-FP-CIT uptake seems to be of limited diagnostic value because of high test-retest variation. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that longitudinal declines in striatal uptake measured using 123[I]-FP-CIT SPECT are associated with MCI due to Lewy body disease but not MCI due to Alzheimer disease.
引用
- Durcan R, Roberts G, Hamilton CA, et al. Serial Nigrostriatal Dopaminergic Imaging in Mild Cognitive Impairment With Lewy Bodies, Alzheimer Disease, and Age-Matched Controls. Neurology. 2023. PMID: 37524532. doi:10.1212/WNL.0000000000207621
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。